Key Points
- DexCom director Bridgette Heller sold 1,012 shares on May 12 at an average price of $60.01, totaling about $60,730.12. After the sale, she still held 25,007 shares, and the trade was made under a pre-arranged Rule 10b5-1 plan.
- DexCom recently beat earnings expectations, reporting Q1 EPS of $0.56 versus the $0.47 consensus and revenue of $1.19 billion versus $1.17 billion expected. Revenue rose 15% year over year, and the company reported strong profitability metrics.
- Wall Street remains broadly positive on DXCM, with a consensus “Moderate Buy” rating and an average price target of $83.22. Several firms recently reiterated or set targets in the $67 to $80 range, though Barclays maintained an underweight rating.
DexCom, Inc. (NASDAQ:DXCM - Get Free Report) Director Bridgette Heller sold 1,012 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director directly owned 25,007 shares in the company, valued at $1,500,670.07. The trade was a 3.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
DexCom Stock Performance
DXCM stock opened at $57.82 on Friday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The business has a 50-day moving average price of $63.69 and a 200 day moving average price of $65.92. The company has a market capitalization of $22.31 billion, a P/E ratio of 24.71, a PEG ratio of 1.01 and a beta of 1.40. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.
DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm's quarterly revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.32 EPS. As a group, equities research analysts forecast that DexCom, Inc. will post 2.56 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on DXCM shares. Mizuho set a $75.00 price objective on shares of DexCom in a report on Friday, May 1st. Barclays set a $67.00 target price on DexCom and gave the stock an "underweight" rating in a report on Friday, May 1st. Robert W. Baird set a $80.00 target price on DexCom in a research report on Friday, May 1st. Weiss Ratings upgraded DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, March 4th. Finally, Citigroup reissued a "buy" rating and issued a $79.00 price target (down from $84.00) on shares of DexCom in a research report on Monday, May 4th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $83.22.
Get Our Latest Analysis on DXCM
Institutional Investors Weigh In On DexCom
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in DexCom by 2.3% in the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company's stock valued at $3,327,897,000 after acquiring an additional 1,133,638 shares in the last quarter. Geode Capital Management LLC increased its position in shares of DexCom by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company's stock worth $727,842,000 after purchasing an additional 42,411 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of DexCom by 6.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company's stock valued at $530,897,000 after purchasing an additional 516,526 shares during the last quarter. Norges Bank purchased a new stake in shares of DexCom during the 4th quarter valued at $483,356,000. Finally, Invesco Ltd. boosted its position in shares of DexCom by 14.8% in the 4th quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company's stock worth $352,781,000 after purchasing an additional 686,228 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.
DexCom Company Profile
(
Get Free Report)
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
